Cramer's Lightning Round: ‘I would not abandon' Cava [CNBC]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: CNBC
Cava : “Cava feels like it has the possibility of being a Chipotle. So, even though I know it just had a big spike, I would not abandon it. I would just look to buy more if it came down.” Rubrik : “It's a good company, but the problem is, again, this market hates enterprise software.” Forward Air : “There's great consolidation happening in this industry.” Bristol Myers Squibb : “Bristol-Meyers has a good dividend, and it's going to take a long time for it to be able to come to fruition, all the things that they want to do. I think it is bottoming...But that doesn't necessarily make us all that excited.” Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter. Sign up now for the CNBC Investing Club to follow Jim Cramer's every move in the market. Disclaimer The CNBC Investing Club Charitable Trust holds shares of Eli Lilly. Questions for Cramer? Call Cramer: 1-800-743-CNBC Want to take a deep dive into
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug [CNBC]CNBC
- New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder [FOX News]FOX News
- BMS wins approval for schizophrenia drug acquired from Karuna [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 7/26/24 - Beat
BMY
Sec Filings
- 8/5/24 - Form 4
- 7/31/24 - Form 4
- 7/31/24 - Form 3/A
- BMY's page on the SEC website